Circulating complexes between @entity5 @entity39 factor-alpha and etanercept predict long-term efficacy of etanercept in XXXX .

@entity1 @entity32 @entity39 @entity5 @entity310 @entity4932
AIM: The relationship between @entity5 @entity39 factor-alpha ( @entity310 ) and drug survival had not been studied in @entity4932 ( @entity4932 ) and there were no laboratory tests to predict the long-term efficacy of biological drugs for @entity4932 . We studied if serum levels of @entity310 , free or bound to etanercept, could predict long-term efficacy of etanercept in @entity1 with @entity4932 . METHODS: We included 41 biologic-na  ve @entity1 with @entity4932 who started treatment with etanercept at Sk  ne University Hospital between 1999-2010. Serum taken at the start of treatment and at the six-week follow up were analysed for @entity310 and the long-term efficacy of etanercept was assessed using the drug survival time. RESULTS: Levels of @entity310 increased significantly at the six-week follow up and this was almost exclusively comprised of @entity310 in complex with etanercept. The increase in @entity310 showed a dose-dependent correlation to long-term drug survival (p < 0.01). CONCLUSION: Increasing levels of circulating @entity310 at treatment initiation predicted long-term efficacy of etanercept in @entity1 with @entity4932 , which may have been due to different pathophysiological mechanisms of @entity32 . Our result may provide a helpful clinical tool, as high levels of circulating @entity310 /etanercept-complexes could be used as a marker for the long-term efficacy of etanercept. This article is protected by copyright. All rights reserved.
